Clinical trial
Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors
NCT00080041 · Pharmacyclics LLC., Industry · Completed
Key facts
| NCT number | NCT00080041 |
|---|---|
| Title | Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors |
| Official title | Phase I Trial of Motexafin Gadolinium (MGd) and Docetaxel Administered at 3-Week Intervals for Advanced Solid Tumors |
| Lead sponsor | Pharmacyclics LLC., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Lung Neoplasms |
| Intervention type | Drug |
| Interventions | Motexafin Gadolinium Injection |
| Enrollment | 20 |
| First posted | Mar 23, 2004 |
| Last update posted | May 15, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: